NovaGo Therapeutics

Focus: NovaGo Therapeutics is a Swiss biotech focused on regeneration therapies following cerebral stroke, operating as an early-stage company in the neurology and cardiovascular space. The company is pre-revenue and in Series A funding stage with a single Phase 1 program.

Neurology Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About NovaGo Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow NovaGo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NG004

Acute Spinal Cord Injury (SCI)

Phase 1

Clinical Trials (1)

NCT06817577NG004 in Spinal Cord Injury Patients

Phase 1

Help build intelligence for NovaGo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in an underserved indication (stroke regeneration) with high unmet medical need and potential for first-mover advantage.
Early-stage biotech allows hands-on involvement across functions and direct impact on compound development from Phase 1 onward.
Based in Zurich with access to Swiss biotech ecosystem and proximity to European regulatory pathways.

Watch Out For

Zero active job openings reported; hiring appears stalled or frozen despite Series A status, signaling potential funding constraints or strategic pause.
Single Phase 1 program (NG004) represents extremely early pipeline with 7+ years to potential approval, creating high career risk and extended dry spell before value inflection.
No revenue, published data, or recent news provided; opacity around financial health, scientific validation, and company momentum raises due diligence red flags.

Generated by Claude from NovaGo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 1 clinical trial

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo